KR20220155316A - 인터루킨-2 돌연변이 및 이의 용도 - Google Patents

인터루킨-2 돌연변이 및 이의 용도 Download PDF

Info

Publication number
KR20220155316A
KR20220155316A KR1020227034880A KR20227034880A KR20220155316A KR 20220155316 A KR20220155316 A KR 20220155316A KR 1020227034880 A KR1020227034880 A KR 1020227034880A KR 20227034880 A KR20227034880 A KR 20227034880A KR 20220155316 A KR20220155316 A KR 20220155316A
Authority
KR
South Korea
Prior art keywords
leu
glu
thr
lys
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227034880A
Other languages
English (en)
Korean (ko)
Inventor
카이지에 헤
펭겐 푸
슈아이시앙 조우
웨이웨이 우
Original Assignee
이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 filed Critical 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드
Publication of KR20220155316A publication Critical patent/KR20220155316A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020227034880A 2020-03-19 2021-03-19 인터루킨-2 돌연변이 및 이의 용도 Pending KR20220155316A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010197740.4 2020-03-19
CN202010197740 2020-03-19
CN202110266549.5 2021-03-11
CN202110266549 2021-03-11
PCT/CN2021/081840 WO2021185361A1 (zh) 2020-03-19 2021-03-19 白介素2突变体及其用途

Publications (1)

Publication Number Publication Date
KR20220155316A true KR20220155316A (ko) 2022-11-22

Family

ID=77770497

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227034880A Pending KR20220155316A (ko) 2020-03-19 2021-03-19 인터루킨-2 돌연변이 및 이의 용도

Country Status (9)

Country Link
US (1) US20230145766A1 (cg-RX-API-DMAC10.html)
EP (1) EP4122952A4 (cg-RX-API-DMAC10.html)
JP (2) JP7879043B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220155316A (cg-RX-API-DMAC10.html)
CN (1) CN115698052A (cg-RX-API-DMAC10.html)
AU (1) AU2021239225B2 (cg-RX-API-DMAC10.html)
CA (1) CA3175717A1 (cg-RX-API-DMAC10.html)
TW (1) TWI790573B (cg-RX-API-DMAC10.html)
WO (1) WO2021185361A1 (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3098930A1 (en) 2018-09-21 2020-03-26 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin-2 and use thereof
CN112105634B (zh) 2018-09-21 2024-03-12 信达生物制药(苏州)有限公司 新型白介素2及其用途
WO2021185362A1 (zh) * 2020-03-19 2021-09-23 信达生物制药(苏州)有限公司 白介素2突变体及其用途
CN118598977A (zh) * 2020-10-18 2024-09-06 北京志道生物科技有限公司 经修饰的il-2分子及其用途
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
TWI825544B (zh) 2020-12-31 2023-12-11 大陸商信達生物製藥(蘇州)有限公司 含異二聚體抗體Fc的蛋白以及其製備方法
JP7864826B2 (ja) * 2021-09-22 2026-05-25 フォートビタ バイオロジクス(シンガポール)プライベート リミティド インターロイキン2変異体およびその融合タンパク質
CN116375879A (zh) * 2021-12-16 2023-07-04 信达生物制药(苏州)有限公司 B7-h3免疫缀合物及其应用
WO2023169524A1 (zh) * 2022-03-10 2023-09-14 广东菲鹏制药股份有限公司 白细胞介素2突变体以及含有其的复合物
IL317511A (en) 2022-06-16 2025-02-01 Cephalon Llc IL-2 immunoconjugates attenuated by anti-PD-1 antibody and their uses
WO2023241653A1 (zh) * 2022-06-17 2023-12-21 舒泰神(北京)生物制药股份有限公司 白介素-2(il-2)突变体及其用途
WO2024008126A1 (en) * 2022-07-06 2024-01-11 Elpiscience (Suzhou) Biopharma, Ltd. Il2 muteins and uses thereof
CN118620056A (zh) * 2023-03-09 2024-09-10 北京天广实生物技术股份有限公司 Il-2变体及其用途
KR20260008731A (ko) * 2023-03-21 2026-01-16 포트비타 바이오로직스 (싱가포르) 피티이. 리미티드 항-pd-1 및 돌연변이 il-2 면역접합체 제제
EP4739334A1 (en) * 2023-07-05 2026-05-13 Nanotein Technologies, Inc. Cell signaling complexes and uses thereof
CN117116336B (zh) * 2023-10-18 2024-01-23 深圳新锐基因科技有限公司 基于内部原子波动改善蛋白结构柔性弱点的方法和装置
IL328822A (en) * 2023-12-19 2026-08-01 Cephalon Llc Uses for attenuated IL-2 immunosuppressants
WO2026012466A1 (en) * 2024-07-12 2026-01-15 Vibrant Pharma Limited Interleukin-2 muteins and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
NZ234674A (en) * 1989-08-02 1992-02-25 Seragen Inc Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
KR20070003934A (ko) * 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
CN105440123B (zh) 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
US9580486B2 (en) * 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
AU2019288496B2 (en) * 2018-06-22 2024-11-21 Cugene Inc. Interleukin-2 variants and methods of uses thereof
CN112105634B (zh) * 2018-09-21 2024-03-12 信达生物制药(苏州)有限公司 新型白介素2及其用途
WO2021185362A1 (zh) * 2020-03-19 2021-09-23 信达生物制药(苏州)有限公司 白介素2突变体及其用途
JP7864826B2 (ja) * 2021-09-22 2026-05-25 フォートビタ バイオロジクス(シンガポール)プライベート リミティド インターロイキン2変異体およびその融合タンパク質

Also Published As

Publication number Publication date
EP4122952A1 (en) 2023-01-25
AU2021239225A1 (en) 2022-10-13
WO2021185361A1 (zh) 2021-09-23
CA3175717A1 (en) 2021-09-23
US20230145766A1 (en) 2023-05-11
JP7879043B2 (ja) 2026-06-23
TWI790573B (zh) 2023-01-21
CN115698052A (zh) 2023-02-03
EP4122952A4 (en) 2024-05-29
JP2026081255A (ja) 2026-05-18
TW202144392A (zh) 2021-12-01
JP2023518434A (ja) 2023-05-01
AU2021239225B2 (en) 2024-08-15

Similar Documents

Publication Publication Date Title
TWI790573B (zh) 白介素2突變體及其用途
CN112105634B (zh) 新型白介素2及其用途
TWI791894B (zh) 新型白介素2及其用途
KR20220155317A (ko) 인터루킨-2 돌연변이 및 이의 용도
US20240391973A1 (en) Interleukin-2 mutant and fusion protein thereof
CA3098765C (en) Novel interleukin-2 and use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000